scholarly journals Helicobacter pyloriEradication in Non-Ulcer Dyspepsia: Clearing up the Controversy

2004 ◽  
Vol 18 (5) ◽  
pp. 339-340
Author(s):  
Carlo A Fallone
Keyword(s):  
Epigastric Pain ◽  
Summary Score ◽  
Care Utilization ◽  
Double Blind ◽  
Physician Visits ◽  
The Mean ◽  
Non Ulcer Dyspepsia ◽  
H Pylori ◽  
The Individual ◽  
Upper Abdominal

Veldhuyzen van Zanten et al conducted a double-blind, randomized, multicentre study comparing triple therapy forHelicobacter pylorieradication to placebo for the treatment of nonulcer dyspepsia (NUD) symptoms in adult patients (1). Patients had moderate to severe epigastric pain on entry (rated at least a three on a five-point scale for at least three of the previous 14 days). The main outcome measure was the Mean Dyspepsia Summary Score (MDSS), which represents the mean severity of eight dyspepsia symptoms (epigastric pain, belching, heartburn, upper abdominal bloating, flatulence, sour taste, nausea and halitosis). Of the 1143 patients who were screened for this study in 27 centres across Canada, 157 were randomized. H pylori was eradicated in 82% of the active group compared with 6% in the placebo group. Symptoms improved in both groups over the 12-month study period, but there was no difference between the two groups in MDSS (2.34 in active and 2.30 in placebo groups at baseline, compared with 1.68 and 1.67, respectively, at the last visit). Nor were there differences in any of the individual symptoms, in the proportion of patients who achieved a certain MDSS score or in health care utilization, such as physician visits, need for additional prescriptions or days lost from work. The authors concluded that, compared with placebo, therapy forH pyloriproduced no sustained improvement of NUD symptoms.

Pirenzepine in Non-Ulcer Dyspepsia: A Double-Blind Multicentre Trial

1990 ◽  
Vol 18 (1) ◽  
pp. 16-20 ◽  
Author(s):  
P.M. Smith ◽  
A.H. Troughton ◽  
F. Gleeson ◽  
J. Walters ◽  
C.F. McCarthy
Keyword(s):  
Abdominal Pain ◽  
Placebo Group ◽  
Adverse Effects ◽  
Multicentre Study ◽  
Multicentre Trial ◽  
Nausea And Vomiting ◽  
Double Blind ◽  
Non Ulcer Dyspepsia ◽  
Upper Abdominal ◽  
To Receive

In a double-blind multicentre study to compare pirenzepine with placebo in non-ulcer dyspepsia, 71 patients were randomized to receive 50 mg pirenzepine or placebo given orally twice daily for 4 weeks. The trial was not completed by five patients in the pirenzepine group and six in the placebo group. There were no significant differences between the groups in respect to changes in total symptoms (upper abdominal pain, nausea and vomiting, early satiety and postprandial bloating, eructation and pyrosis) scores and outcome, although 27/35 (77%) patients receiving pirenzepine were cured or improved compared with 22/36 (61%) receiving the placebo. Adverse effects were reported by 13 (37%) patients treated with pirenzepine and by six (17%) treated with placebo, seven withdrawing due to adverse effects.

scholarly journals Morphology of abdominal pain: the inside story; investigation of abdominal pain and its correlation with endoscopy and H. pylori status

2019 ◽  
Vol 6 (5) ◽  
pp. 1740
Author(s):  
M. K. Saxena ◽  
Rooman Ahmad Rana ◽  
Ashutosh Gupta ◽  
Ausaf Ahmad
Keyword(s):  
Abdominal Pain ◽  
Epigastric Pain ◽  
Statistical Significance ◽  
Exclusion Criteria ◽  
Carcinogenic Effect ◽  
Background Pain ◽  
H Pylori ◽  
The Individual ◽  
Upper Abdomen

Background: Pain in the abdomen especially upper abdomen is a common presentation in any clinicians OPD. It has a significant effect on the quality of life of the individual. Moreover, it is essential to exclude presence of H. pylori infection since it is known to have carcinogenic effect, as well as the propensity to develop duodenal ulcer. This study was undertaken to understand the association of the above-mentioned symptoms with endoscopic findings and with H. pylori infection, and to find out if there is significant correlation between the above-mentioned symptoms and presence or absence of H. pylori infection.Methods: This is a retrospective descriptive study based on the upper GI endoscopies carried out in the institution. The period covered was from 01 January 2018 to 31 December 2018. The inclusion and exclusion criteria were well defined. Data on patients presenting with symptoms of Gastritis, dyspepsia, epigastric pain and upper abdomen pain was studied.Results: The study showed association between age and H. pylori infection though it was not found to be statistically significant. The association between significant endoscopic finding and H. pylori was statistically significant (p>0.05) epigastric pain as a symptom was found to have strong Statistical significance with presence of H. pylori (p<0.05).Conclusions: Patients presenting with the symptoms of Gastritis, dyspepsia, epigastric pain and upper abdomen pain be investigated and endoscopy and biopsy for H. pylori should be part of protocol for their management.

scholarly journals HELICOBACTER PYLORI

2018 ◽  
Vol 21 (04) ◽  
pp. 679-683
Author(s):  
Shuaib Ansari ◽  
Irfan Murtaza Shahwani ◽  
Aqeel Ahmed Channa ◽  
Syed Zulfiquar Ali Shah ◽  
Tarachand Devrajani
Keyword(s):  
Functional Dyspepsia ◽  
Histopathological Examination ◽  
Epigastric Pain ◽  
P Value ◽  
Male Population ◽  
Low Socioeconomic ◽  
Multidisciplinary Study ◽  
History Of ◽  
The Mean ◽  
H Pylori

Objective: To determine the frequency of H. pylori in patients with functionaldyspepsia. Patients and methods: This six months multidisciplinary study was conducted attertiary care teaching hospital as well as at private hospital Hyderabad from February 2012 to July2012. All patients presented with history of dyspepsia were admitted and evaluated for functionaldyspepsia by performing endoscopy. After confirmation of functional dyspepsia the subjectswere further evaluated for H. pylori infection by taking the biopsy specimen, label it and sent tolaboratory for histopathological examination. The data was entered, saved and analyzed in SPSSversion 11.00. Results: During six month study period, total 100 patients with functionaldyspepsia were recruited. Majority of patients were from low socioeconomic class (78%), havehistory of spicy food intake (68%) and epigastric pain (94%). The associated symptoms observedwere nausea and vomiting (87%), anorexia (88%), early satiety (84%) and regurgitation (84%).The mean ±SD for age of patients with functional dyspepsia was 37.95±10.85. The mean age±SD of H. pylori identified patients was 35.81±7.72. Majority of the subjects was 30-40 years ofage and the male population predominant 64% (p-value 0.02, statistically significant). The H.pylori was identified in 62% of patients, of which 35 (56.5%) were males and 27(43.5%) werefemales (p-value 0.04, statistically significant) respectively.

scholarly journals Effects ofLactobacillus gasseriOLL2716 onHelicobacter pylori-Associated Dyspepsia: A Multicenter Randomized Double-Blind Controlled Trial

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Atsushi Takagi ◽  
Hidetaka Yanagi ◽  
Hideki Ozawa ◽  
Naomi Uemura ◽  
Shigemi Nakajima ◽  
...  
Keyword(s):  
Epigastric Pain ◽  
Controlled Trial ◽  
Gastrointestinal Symptoms ◽  
University Hospital ◽  
Clinical Trial Registry ◽  
Double Blind ◽  
Postprandial Fullness ◽  
Medical Network ◽  
H Pylori ◽  
The University

SomeLactobacillusspp. suppressHelicobacter pyloriin the stomach and have potential therapeutic applications for the treatment of gastrointestinal conditions. In this study, the effects ofLactobacillusstrains on functional dyspepsia associated withH. pyloriinfection were examined. Volunteers were screened using the13C-urea breath test (UBT) andH. pyloristool test, and 131 participants who met the selection criteria (mean age: 48.9 years) were randomly givenL. gasseriOLL2716-containing yogurt or placebo yogurt once daily for 12 weeks. Gastrointestinal symptoms (epigastric pain, bloating, postprandial fullness, nausea, and heartburn) and the levels of serum pepsinogen (PG),13C-UBT, andH. pyloristool antigen were assessed. No significant differences were observed between the groups in UBT results,H. pyloristool antigens, or the serum PGI/II ratio. In theL. gasserigroup, postprandial fullness was significantly lower at the end of the trial compared to the initial level (p<0.05) and significantly fewer patients had a VAS score of >10 for bloating compared to the placebo group (p<0.05). Dietary supplementation withL. gasseriOLL2716-containing yogurt may effectively suppress dyspeptic symptoms inH. pylori-infected patients. This study was registered at the University Hospital Medical Network Clinical Trial Registry (UMIN000016746).

scholarly journals Frequency of helicobacter pylori in patients with functional dyspepsia.

2019 ◽  
Vol 26 (08) ◽  
pp. 1261-1265
Author(s):  
Tooba ◽  
Riaz Hussain Awan ◽  
Seema Nayab ◽  
Khadim Hussain Awan ◽  
Faqir Muhammad Awan
Keyword(s):  
Helicobacter Pylori ◽  
Functional Dyspepsia ◽  
Histopathological Examination ◽  
Epigastric Pain ◽  
Helicobacter Pylori Infection ◽  
Cross Sectional ◽  
Male Predominance ◽  
Duration Of Disease ◽  
The Mean ◽  
H Pylori

To evaluate the frequency of Helicobacter pylori in individuals with functional dyspepsia. Study Design: Cross sectional descriptive study. Period: Six months from 01-May-2014 to 31-10-2014. Setting: Liaquat National Hospital, Karachi. Materials and Methods: All the patients between 18 to 70 years of age diagnosed as functional dyspepsia for more than 03 months duration were admitted and evaluated for Helicobacter pylori infection through histopathological examination. Results: Total 121 subjects with functional dyspepsia were screened for Helicobacter pylori infection. The mean ±SD for age of subjects with functional dyspepsia was 41.74±08.87. The mean age ±SD of Helicobacter pylori infected individuals was 40.70±7.82 while the mean ±SD of age in helicobacter pylori negative patients was 40.55±10.63. Majority of the subjects were out-patients, 30-39 years of age with male predominance. The most common duration of disease observed was 6-9 months with epigastric pain and burning the predominant symptoms. The Helicobacter pylori infection was observed in 78(64.4%) individuals, of which 55 were males and 23 were males (p=<0.01). Conclusion: The functional dyspeptic patients are prone to acquire Helicobacter pylori infection therefore present study reported 64.4% prevalence for H. pylori infection with male gender predominance.

Effects of NEPA (novel combination of netupitant and palonosetron) on ECG of healthy volunteers: A randomized, controlled, thorough ECG trial.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20538-e20538
Author(s):  
Tulla Spinelli ◽  
Cecilia Moresino ◽  
Sybille Baumann ◽  
Wolfgang Timmer
Keyword(s):  
Heart Rate ◽  
Primary Objective ◽  
Fixed Dose ◽  
Controlled Study ◽  
Open Label ◽  
Double Blind ◽  
Supportive Cancer Care ◽  
Ich E14 ◽  
The Individual ◽  
Upper Abdominal

e20538 Background: Despite advances in supportive cancer care, chemotherapy-induced nausea and vomiting (CINV) is ranked by patients among the worst side effects of chemotherapy. NEPA is a new antiemetic under development composed of a unique fixed-dose combination of netupitant (NETU, 300 mg), a new, highly selective NK1 receptor antagonist (RA), and palonosetron (PALO, 0.5 mg), a pharmacologically and clinically distinct 5-HT3RA. NEPA targets the 2 most important emetic pathways with a single oral dose. Although PALO is not associated with cardiovascular issues, this study aimed to evaluate the tolerability and cardiovascular safety of different doses of NETU + PALO. Methods: This randomized, double-blind, parallel-group, placebo- and open-label positive-controlled study in 197 volunteers (106 men) included 4 treatment groups: placebo, 200 mg NETU + 0.5 mg PALO (NEPA 200/0.5), 600 mg NETU + 1.5 mg PALO (NEPA 600/1.5), and 400 mg moxifloxacin. Assessments, based on ICH E14 Guidelines, included a 24-h baseline ECG after which volunteers received a single dose of treatment, followed by ECG measurements for 2 days. The primary objective was to determine the individual heart rate-corrected QT interval (QTcI) (n=196). Safety and tolerability of NEPA groups were also assessed (n=197). Results: Mean placebo-corrected QTcI change from baseline was +5 and +4 ms for NEPA200/0.5 and NEPA600/1.5, respectively. Mean placebo-corrected change from baseline for heart rate (HR) was -3 bpm for the 2 NEPA groups. Placebo-corrected changes in pulse rate (PR) and QRS durations were similar in both NEPA groups (0 to 1 ms) and not clinically different from placebo. These data show no signs of an effect of NEPA groups on QTcI. In comparison, the moxifloxacin showed the expected increase in QTcI vs placebo (+8/9 ms). The frequency of all treatment-related AEs (TRAEs) for NEPA200/0.5 was lower than placebo but slightly higher in volunteers treated with NEPA600/1.5. The most commonly reported TRAEs in the NEPA groups were constipation, upper abdominal pain, and headache. Conclusions: NEPA treatments produced no significant effects on QTcI, HR, PR, QRS interval, or cardiac morphology relative to placebo.

scholarly journals GASTRIC PATHOLOGY

2018 ◽  
Vol 25 (12) ◽  
pp. 1905-1909
Author(s):  
Shahnawaz Tahir ◽  
Riaz Hussain Awan ◽  
Seema Nayab ◽  
Khadim Hussain Awan
Keyword(s):  
Clinical Laboratory ◽  
Epigastric Pain ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Gastric Pathology ◽  
History Of ◽  
The Mean ◽  
H Pylori ◽  
Histopathological Type ◽  
Study Setting

Objectives: To determine the frequency & histopathological type of gastric pathology in individuals presenting with epigastric pain. Period: Six months from July to Dec 2017. Study Design: Cross sectional study. Setting: Department of Gastroenterology, Liaquat National Hospital Institute for Postgraduate Medical Studies and Health Sciences, Karachi. Patients and Methods: The total of 333 patients had history of epigastric pain were included in this study. The specimen for mucosal biopsy was taken during endoscopy and sent to the clinical laboratory for histopathology examination for the classification. All the information was entered and saved on the annexed / proforma. Results: The mean ±SD of age for all thepatients was 41.31±7.89 years. Frequency of gastric pathology in patient presenting with epigastric pain was 51.35% (171/333) cases. There were 171 histopatholocal diagnoses, non-Noeplastic lesion was confirmed in 99.42% (170/177) and one case had Noeplastic lesion. Regarding the type of gastric pathology, 25.73 % (44/171) had gastric ulcer, 48.54 (83/171) was H. pylori gastric and 25.15% (43/171) had chronic gastritis. Conclusion: The study frequency of gastric pathology in patient presenting with epigastric pain was high.

The Antiaggressive Action of Combined Haloperidol-Propranolol Treatment in Schizophrenia

2000 ◽  
Vol 5 (4) ◽  
pp. 312-325 ◽  
Author(s):  
Gadi Maoz ◽  
Daniel Stein ◽  
Sorin Meged ◽  
Larisa Kurzman ◽  
Joseph Levine ◽  
...  
Keyword(s):  
Rating Scales ◽  
Double Blind ◽  
Propranolol Group ◽  
Schizophrenic Patients ◽  
Propranolol Treatment ◽  
Simultaneous Decrease ◽  
The Mean ◽  
Haloperidol Treatment ◽  
To Receive ◽  
Drug Free

Psychopharmacological interventions for managing aggression in schizophrenia have thus far yielded inconsistent results. This study evaluates the antiaggressive efficacy of combined haloperidol-propranolol treatment. Thirty-four newly admitted schizophrenic patients were studied in a controlled double-blind trial. Following a 3-day drug-free period and 7 days of haloperidol treatment, patients were randomly assigned to receive either haloperidol-propranolol or haloperidol-placebo for eight consecutive weeks. Doses of medications were adjusted as necessary; biperiden was administered if required. Rating scales were applied to assess aggression, anger, psychosis, depression, anxiety and extrapyramidal symptoms. The mean daily dose of haloperidol was 21 mg (SD = 6.4) in the research group and 29 mg (SD = 6.9) in the controls. Mean and maximal daily doses of propranolol were 159 mg (SD = 61) and 192 mg (SD = 83), and of placebo, 145 mg (SD = 50) and 180 mg (SD = 70), respectively. Compared with the controls, the scores for the research patients decreased significantly from baseline, particularly after 4 weeks of treatment, for some dimensions of anger, psychosis, anxiety, and neuroleptic-induced parkinsonism. A tendency for reduced aggression was shown in the combined haloperidol-propranolol group for some dimensions but not others. These patients also required significantly less biperiden. The tendency toward elevated antiaggressive effect of combined haloperidol-propranolol treatment compared to haloperidol alone may be explained by a simultaneous decrease in aggression, psychotic symptomatology, and anxiety.

Sign in / Sign up

Export Citation Format

Share Document